Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease

Completed · Phase 2

Conditions studied: Alzheimer Disease, Parkinson Disease

In brief

The underlying goal of this study is to assess 123-I IBVM SPECT imaging as a tool to assess cholinergic transporter binding in the brain of AD and PD research participants and age- and gender-matched healthy subjects.

Key facts

Study ID

NCT00480701

Run by

Institute for Neurodegenerative Disorders

People needed

26

Starts

2007-02-01

Expected to finish

2011-10-01

Last updated by the study team

2014-05-07

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: accepted.

Where it is running

• Institute for Neurodegenerative Disorders — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.